Copper Peptides
A family of small copper-binding tripeptides — GHK-Cu, AHK-Cu, and palmitoyl variants — that form stable copper(II) complexes with documented effects on collagen synthesis, wound healing, and skin remodeling. Founded by Loren Pickart's 1973 isolation of GHK-Cu and now a fixture of cosmetic dermatology and the wound-care literature.
Copper peptides are small copper-binding peptides — most prominently the tripeptide GHK and its cousins AHK and various palmitoylated derivatives — that form stable square-planar complexes with copper(II) ions and exert biological effects on collagen synthesis, wound healing, hair follicle activity, antioxidant signaling, and skin remodeling. The class was founded by Loren Pickart in the early 1970s. His 1973 Biochemical and Biophysical Research Communications paper reported that a synthetic tripeptide (later identified as Gly-His-Lys, GHK) increased the survival of normal liver cells in culture and modulated hepatoma cell growth — the founding observation of the copper-peptide class, with the active form ultimately characterized as a copper(II) coordination complex. Over the following five decades, GHK-Cu and its analogs have been characterized at the gene-expression level (the Broad Institute Connectivity Map analysis underlying Pickart's 'GHK and DNA' 2014 review identified coordinated effects across thousands of human genes), in animal wound-healing models (Maquart's 1988 FEBS Letters and 1993 J Clin Invest papers), in cosmeceutical formulations, and in human clinical trials including a 100-patient RCT of post-CO₂ laser resurfacing wound healing. Copper peptides now sit firmly in the cosmetic dermatology, wound-care, and topical anti-aging segments — they are not approved as therapeutics for systemic disease, but they have one of the better-characterized topical evidence bases in the peptide world, and they are among the most-searched peptide categories in consumer dermatology.
This page is the family-level pillar covering the copper-peptide class as a whole. For individual peptide pages with full evidence ratings, dosing, and references, follow the links to GHK-Cu, AHK-Cu, and Palmitoyl-AHK below. For the cosmetic peptide cluster more broadly (signal peptides, neurotransmitter-inhibiting peptides, carrier peptides), see the related Cosmetic Peptides family page.
Peptides in Copper Peptides
GHK-Cu
Copper Peptide
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
AHK-Cu
Copper Peptide
A copper peptide — the copper-complexed tripeptide alanine-histidine-lysine (AHK-Cu, Copper Tripeptide-3) — studied for hair follicle stimulation and dermal papilla cell survival. A structural cousin of the better-known copper peptide GHK-Cu with a distinct, hair-focused research profile.
Pal-AHK
Cosmeceutical Peptide
A palmitoylated cosmeceutical tripeptide (Ala-His-Lys) studied for hair growth stimulation via dermal papilla cell proliferation and anti-apoptotic signaling, as well as collagen synthesis and skin rejuvenation.
Other members of the class
GHK (the free tripeptide)
Glycyl-L-histidyl-L-lysine without bound copper. Substantially less active than the GHK-Cu complex — the copper coordination is what produces most of the documented biology.
Iamin (GHL)
An older copper-peptide name (Procyte Corporation), now generally referred to as GHK-Cu. Historically marketed as a wound-healing formulation.
Tripeptide-1 / Tripeptide-3 in cosmetic INCI naming
Cosmetic-ingredient-list nomenclature for various tripeptides including GHK and analogs — frequently appears alongside or in place of named copper-peptide labeling.
Shared mechanism
All members of the copper-peptide family share the same fundamental mechanism: a small peptide forms a stable square-planar coordination complex with copper(II), and the resulting complex acts as a copper-delivery and signaling agent at target tissues. The peptide-Cu(II) coordination is established through an N-terminal amino-acid nitrogen, the imidazole nitrogen of histidine (typically at position 2), and additional coordinating sites — producing a thermodynamically stable complex with characteristic blue-purple color and well-defined pharmacology.
Downstream effects span four categories. First, copper-cofactor delivery: copper-peptide complexes function as physiological copper carriers in plasma and extracellular fluid, releasing copper to copper-dependent enzymes including lysyl oxidase (which crosslinks collagen and elastin), superoxide dismutase (antioxidant defense), and ceruloplasmin. Second, gene-expression effects: the 2010 Broad Institute Connectivity Map analysis showed that GHK-Cu coordinates expression changes across approximately 4,000 human genes, including upregulation of genes for collagen synthesis, decorin, metalloproteinases, antioxidant pathways, and the ubiquitin-proteasome system that clears damaged proteins. Third, anti-inflammatory and tissue-remodeling effects: copper peptides reduce TNF-α and other inflammatory cytokines, modulate macrophage polarization, and stimulate fibroblast proliferation and collagen synthesis. Fourth, hair-follicle effects (more peptide-specific): AHK-Cu in particular has documented anti-apoptotic effects on dermal papilla cells with VEGF upregulation, providing a candidate mechanism for hair-growth applications.
Formulation considerations are shared across the class. Copper peptide complexes are stable at neutral pH but destabilize under acidic conditions — making them incompatible with co-application of high-concentration vitamin C (L-ascorbic acid), strong AHA/BHA exfoliants, or other low-pH actives in the same product layer or time of day. Multi-peptide cosmetic formulations frequently combine copper peptides with matrikines, antioxidants, hydration agents, and biotin, with the formulation goal of complementary rather than competing pathway engagement.
History & discovery
The copper-peptide story begins with Loren Pickart's 1973 Biochemical and Biophysical Research Communications paper, which reported that a synthetic tripeptide increased the survival of normal liver cells in culture while modulating hepatoma cell growth. The peptide was Gly-His-Lys (GHK), and the active form turned out to be a copper(II) coordination complex (GHK-Cu) — the foundational observation that defined the copper-peptide class. Pickart's broader research narrative was framed around why young human plasma supported cell function more effectively than plasma from older donors, and the GHK-Cu discovery emerged from that line of work.
Over the 1980s and 1990s Pickart and collaborators (notably François-Xavier Maquart's group in France) characterized GHK-Cu's biological effects across multiple tissue systems. Maquart's 1988 FEBS Letters paper established stimulation of collagen synthesis in fibroblast cultures by the GHK-Cu complex, and the 1993 Journal of Clinical Investigation paper extended the work to in vivo connective tissue accumulation in rat experimental wounds. The 2000 Siméon Journal of Investigative Dermatology paper documented effects on glycosaminoglycans and small proteoglycans in wound models. The work expanded into cosmetic dermatology when topical copper-peptide formulations entered the cosmeceutical market in the 1990s and 2000s, with brand names including Neutrogena Visibly Firm, Neova, and others. Procyte Corporation (which Pickart founded) developed copper-peptide products for both cosmetic and clinical wound-care indications.
AHK-Cu emerged in the 2000s as a second-generation copper peptide focused on hair-follicle biology. The 2007 Pyo et al. in vitro and ex vivo study in Archives of Pharmacal Research demonstrated that the tripeptide-copper complex AHK-Cu at picomolar to nanomolar concentrations stimulated human hair follicle elongation and dermal papilla cell proliferation, with anti-apoptotic signatures (elevated Bcl-2/Bax ratio, reduced caspase-3 and PARP cleavage) and VEGF upregulation. AHK-Cu and its palmitoylated derivative Palmitoyl-AHK (Pal-AHK) entered the cosmetic-ingredient market for hair-loss formulations, often paired with GHK-Cu in multi-peptide blends.
The modern era of copper-peptide research has been defined by the Broad Institute Connectivity Map gene-expression analysis underlying Pickart's 2014 'GHK and DNA' BioMed Research International review and the 2018 'Regenerative and Protective Actions' International Journal of Molecular Sciences review — together documenting GHK-Cu's effects across thousands of human genes spanning collagen synthesis, antioxidant pathways, the ubiquitin-proteasome system, and disease-modulating gene patterns. The 2007 Abdulghani et al. randomized controlled trial of GHK-Cu in 100 patients post-CO₂ laser resurfacing established the strongest single piece of human clinical evidence for the class. As of 2026, GHK-Cu is one of the better-characterized topical actives in cosmetic dermatology, while AHK-Cu remains supported primarily by the 2007 Pyo paper plus mechanistic and formulation work that has not progressed to controlled human trials.
State of evidence
Evidence across the copper-peptide class is uneven by member. GHK-Cu has the strongest evidence base in the family — five decades of in vitro (Maquart 1988 fibroblast collagen synthesis), in vivo animal (Maquart 1993 rat wound healing; Siméon 2000 wound proteoglycans), and human clinical work (the 2007 Abdulghani RCT in 100 patients post-CO₂ laser resurfacing), plus the gene-expression breadth documented in Pickart's Connectivity Map analyses. Site confidence for GHK-Cu sits around 70%. AHK-Cu has a thinner evidence base built primarily on the 2007 Pyo et al. in vitro and ex vivo study showing dermal-papilla and hair-follicle activity, with limited independent peer-reviewed replication and no human clinical trial for hair growth, skin aging, or other endpoints — site confidence sits around 20%. Palmitoyl-AHK is the cosmetic-formulation derivative of AHK and shares AHK's evidence base, with the palmitoylation primarily affecting skin penetration rather than introducing new pharmacology.
For consumers, the practical takeaway is that 'copper peptide' is not a single uniform category. GHK-Cu products are supported by real evidence for collagen stimulation, wound healing, and photoaging adjunct use — not as a substitute for FDA-approved interventions like topical tretinoin, but as a complementary cosmetic active. AHK-Cu products marketed for hair growth rest on a thinner mechanistic case with no clinical validation; for androgenetic alopecia the evidence-supported options remain minoxidil and finasteride. Multi-peptide blends combining GHK-Cu and AHK-Cu are common in the cosmetic market on the theory that they engage complementary pathways (skin layer + follicular layer), but no head-to-head or combination-vs-single-peptide controlled trial has tested this assumption.
How members compare
Within the copper-peptide family, the principal comparison is GHK-Cu vs AHK-Cu — see the dedicated /compare/ghk-cu-vs-ahk-cu page for the full table. Briefly: GHK-Cu has the deeper evidence base (collagen, wound healing, photoaging — strong RCT support), AHK-Cu has the more specific mechanism (hair follicle anti-apoptosis, dermal papilla proliferation — limited to one foundational paper). Palmitoyl-AHK is the cosmetic-penetration-optimized variant of AHK-Cu and shares its evidence profile.
Outside the copper-peptide family, the relevant comparisons depend on the goal. For collagen stimulation and photoaging: copper peptides plus topical retinoids plus matrikines (palmitoyl tripeptide-1, matrixyl) is the standard cosmetic stack — the retinoid does the heavy lifting, the copper peptides and matrikines supplement. For hair growth: copper peptides are not the evidence-supported first-line — minoxidil (topical or oral), finasteride (5α-reductase inhibition), and dutasteride dominate the validated literature; copper peptides are adjuncts, not primary therapies. For wound healing: GHK-Cu has been studied in clinical settings (post-laser resurfacing, diabetic ulcers in some smaller studies) but again sits as adjunct rather than primary care.
Frequently asked questions
Are all copper peptides the same?
No. The family includes GHK-Cu (the original and best-evidenced member), AHK-Cu (a hair-follicle-focused cousin with much thinner evidence), and Palmitoyl-AHK (a penetration-optimized cosmetic variant of AHK-Cu). They share the copper-binding mechanism but have meaningfully different evidence bases and use cases. Cosmetic marketing that uses 'copper peptides' as a generic category obscures these differences.
Do copper peptides actually work for skin?
GHK-Cu has reasonable evidence for collagen stimulation, post-laser resurfacing wound healing, and adjunct photoaging benefit — site confidence around 70%. The strongest claim is post-CO₂ laser resurfacing, where multiple human studies support GHK-Cu in topical recovery formulations. For everyday photoaging, GHK-Cu is a reasonable cosmetic adjunct alongside topical retinoids (which carry stronger evidence as a primary active). The evidence does not support copper peptides as a substitute for retinoid-based anti-aging regimens.
Do copper peptides work for hair loss?
The evidence is limited. AHK-Cu has a credible molecular-level mechanism for promoting hair follicle elongation (the 2007 Pyo et al. paper), but independent replication is sparse and no human clinical trial for hair growth has been published. For androgenetic alopecia, the evidence-supported options are minoxidil (topical or oral) and 5α-reductase inhibitors (finasteride, dutasteride). Copper peptides marketed for hair loss should be understood as adjuncts with thin evidence, not validated treatments.
Can I combine copper peptides with retinol or vitamin C?
Combine carefully. Copper peptide complexes are stable at neutral pH but destabilize under acidic conditions, which makes them incompatible with co-application of high-concentration vitamin C (L-ascorbic acid) or strong AHA/BHA exfoliants in the same product layer or time of day. The typical solution is morning/evening separation: vitamin C in the morning, copper peptides in the evening (or vice versa). Retinol is more compatible because retinol formulations are typically not at the very low pH of vitamin C, but spacing them by a few hours is still common formulation practice.
Are copper peptides FDA-approved?
No copper peptide is FDA-approved as a drug for any indication. Copper-peptide products in the U.S. market are sold as cosmetic ingredients and are subject to cosmetic labeling rules rather than drug approval. Some clinical-grade GHK-Cu preparations have been studied in regulated trials for wound-healing indications, but no copper peptide has reached drug approval. Anyone seeking treatment for a skin or hair condition should not substitute copper peptide cosmetics for FDA-approved interventions where validated options exist.
Are copper peptides safe?
Topical copper peptide cosmetics have a generally favorable safety profile in cosmetic-use settings, with the principal concerns being copper-related sensitivity in some individuals and formulation-incompatibility-induced destabilization. Systemic or injected copper peptides are not standard practice and have not been characterized to the same standards as topical use. Anyone with copper sensitivity, Wilson's disease, or other copper-metabolism disorders should avoid copper-peptide products. Patients undergoing dermatologic procedures should consult their clinician before integrating copper-peptide products into recovery routines.
References
- A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cellsOriginal Research
Pickart L, Biochemical and Biophysical Research Communications 1973. The founding paper of the copper-peptide class, reporting that a synthetic tripeptide (later identified as GHK) increased normal liver cell survival in culture and modulated hepatoma cell growth — the observation that started Pickart's five-decade investigation of GHK-Cu biology.
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationReview
Pickart L, Vasquez-Soltero JM, and Margolina A, BioMed Research International 2015. Comprehensive review of GHK-Cu biology covering wound healing, collagen synthesis, gene-expression effects, anti-inflammatory actions, and clinical evidence. Standard single-source reference for the GHK-Cu skin-regeneration literature.
- The effect of tripeptide-copper complex on human hair growth in vitroOriginal Research
Pyo HK and colleagues, Archives of Pharmacal Research 2007. The principal mechanistic paper for AHK-Cu in hair-follicle biology, showing dermal papilla cell proliferation, anti-apoptotic signatures (Bcl-2/Bax, caspase-3, PARP), and VEGF upregulation. The basis for most AHK-Cu hair-growth claims and the dominant single source supporting the AHK-Cu evidence base.
- GHK and DNA: resetting the human genome to healthReview
Pickart L, Vasquez-Soltero JM, and Margolina A, BioMed Research International 2014. Reviews the gene-expression effects of GHK-Cu identified in the Broad Institute Connectivity Map analysis, showing coordinated effects across thousands of human genes including collagen synthesis, antioxidant pathways, and protein quality control.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataReview
Pickart L and Margolina A, International Journal of Molecular Sciences 2018. Updated review of GHK-Cu biology in light of expanded Connectivity Map data, characterizing regenerative and protective gene-expression actions across tissue repair, anti-cancer, and anti-inflammatory pathways. The most comprehensive recent single-source overview.
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinClinical Trial
Randomized controlled trial in 100 patients demonstrating that topical GHK-Cu significantly accelerated wound healing after CO₂ laser resurfacing, with faster re-epithelialization and reduced erythema versus placebo. The strongest single piece of human clinical evidence for the copper-peptide class.
- Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+Original Research
Maquart FX and colleagues, FEBS Letters 1988. Established stimulation of collagen synthesis in cultured fibroblasts by the GHK-Cu complex — the foundational in vitro paper for the collagen-stimulation mechanism that anchors GHK-Cu's cosmetic dermatology applications.
- In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental woundsOriginal Research
Maquart FX and colleagues, Journal of Clinical Investigation 1993. Extended the GHK-Cu collagen-stimulation work into in vivo rat wound healing, demonstrating connective tissue accumulation under the GHK-Cu intervention.
- Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+)Original Research